Clinical Studies/Trials

Another fascinating study shows a positive effect of stem cell infusion in post-infarct patients when compared with standard of care control group.

Regulatory approval is one step closer with Boston Scientific’s announcement that its REPRISE I Clinical trial of the Lotus TAVR system has completed enrollment.

Israeli company Brainsway put its money where its mouth is when it undertook a major clinical study into the effect of its therapy on unresponsive depression sufferers. The results suggest it paid off as significant improvements were noted in the treatment group.

Turmeric is supposed to be good for us, but now its beginning to look like a wonder spice as researchers suggest it can reduce post cardiac surgical incidence of heart attack in a placebo study.

When is a published paper a thinly disguised marketing study? One man clearly has a view.

Medtronic’s clinical ambitions are laid bare at CX34 as it announces the imminent start of its 1500 patient evaluation of peripheral artery treatment using its IN.PACT Drug-eluting balloon.

Aussie regenerative medicine outfit Mesoblast Ltd is making great progress with its US phase 2 study into the effect of stem cell injections in mitigating low back pain.

More from CX34 as Medtronic’s Endurant AAA Stent Graft 2 year data gets a positive airing.

Stenting still has a way to go if it’s to persuade the vascular community it’s a routine alternative to Carotid Endarterectomy.

The first patient has been implanted with St.Jude’s Accent MRI® Pacemaker in a study to determine whether the device will be compatible with full body MRI scans once in situ.

Endovascular aneurysm repair looks like it can be supported in ruptured aneurysms, but other factors need to be taken into account as real-world studies from two Swiss Centres don’t harmonise.

Bioabsorbable stents are back in the news with the publication of ten year data from Japan claiming safety at ten years in a 50 patient study.

As public spats go, this one is going to take some beating. St. Jude is not looking like its in the mood to give up as it comes right back at Medtronic, Dr Hauser and Heart Rhythm.

Achieving device approval in Japan is a major undertaking, so Abbott must be delighted that its Xience Prime everolimus eluting stent has got the nod based on a robust body of clinical evidence.

Predictaresponse time. Heart Rhythm has refused to retract, which it was always likely to do. St. Jude might get the chance to respond in public as the journal offers to review its data.

Medtronic declares itself pleased, but in reality must be absolutely delighted by the news that FDA has allowed it to expand the indications for its CRT-D resynchronisation/defibrillator devices to now include patients with mildly symptomatic heart failure.